Developing Integrin Activators

as First-In-Class Kidney Disease Therapeutics
Learn More about our mission

Our Lead

Ontegimod – A clinical stage, oral, selective, small molecule integrin CD11b agonist for the treatment of lupus nephritis.

Our CellStaple Platform

Our Proprietary AI-enabled CellStaple Platform Identifies Novel Antibody and Small Molecule Therapeutics

Career Opportunities

AlloSite is growing. Apply below

© 2023 AlloSite Therapeutics.       All rights reserved.